


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Currently Amended) A compound Compounds of the formula

I



in which

R¹ is H, OH, CN, Hal, CONHR, OB, CO₂B, CF₃, NR₂, NRCOR, NRCOOR or NRCONR₂,

R² is NR₂, NRCOR, NRCOOR, NRCONR₂, NO₂, NRSO₂R₂, NRCSR or NRCSNR₂,

R³ is H, OH, CN, Hal, CONHR, OB, CO₂B, CF₃, NO₂, NR₂, NRCOR, NRCOOR or NRCONR₂,

R, independently of one another, are H, B, Het or Ar,

A is a straight-chain or branched, mono- or polyunsaturated carbon chain having 2, 3, 4, 5, or 6 carbon atoms,

B is a straight-chain or branched alkyl radical having 1, 2, 3, 4, 5 or 6 carbon atoms,

a and pharmaceutically usable prodrug[[s]], derivative[[s]], solvate[[s]], stereoisomer[[s]] and salt[[s]] thereof, or a and mixture[[s]] thereof in all ratios.

Claim 2 **(Currently Amended)** A compound Compounds-of the formula I according to Claim 1, wherein characterised in that the radical R¹ is CN or Hal, preferably CN.

Claim 3 **(Currently Amended)** A compound Compounds-of the formula I according to Claim 1, wherein characterised in that the radical R³ is H.

Claim 4 **(Currently Amended)** A compound Compounds-of the formula I according to Claim 1 wherein characterised in that the radical R² is NRCOR or NRCOOR.

Claim 5 **(Currently Amended)** A compound Compounds-of the formula I according to Claim 1, wherein characterised in that A is $(CH_2)_m$, where m = 2, 3, 4, 5 or 6, preferably 4.

Claim 6 **(Currently Amended)** A compound Compounds-of the formula I according to Claim 1, wherein characterised in that the radical R¹ is CN or Hal, where CN is preferred, and R³ is H.

Claim 7 **(Currently Amended)** A compound Compounds-of the formula I according to Claim 1, wherein characterised in that R¹ is CN, R³ is H, and A is $(CH_2)_m$, where m = 4.

Claim 8 **(Currently Amended)** A compound Compounds-of the formula I according to Claim 1, wherein characterised in that the radical R¹ is in position 5 of the indole radical.

Claim 9 **(Currently Amended)** A compound Compounds-of the formula I which is selected from the group consisting of
N-(6-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)methylamide,

ethyl (6-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)carbamate,


methyl N-(6-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)carbamate,

N-(6-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)-2,2-dimethylpropionamide,


3-{4-[4-(3-amino-2-oxo-2H-chromen-6-yl)piperazin-1-yl]butyl}-1H-indole-5-carbonitrile,

or a ~~and~~-pharmaceutically usable prodrug[[s]], derivative[[s]], solvate[[s]], stereoisomer[[s]] or ~~and~~ salt[[s]] thereof.

Claim 10 (Currently Amended) A process for the preparation of compounds of the formula I according to Claim 1, comprising reacting characterised in that a compound of the formula II




in which R² and R³ are as defined in Claim 1, is reacted with a compound of the formula III




in which R¹ and A are as defined in Claim 1, and L is Cl, Br, I, OH or a reactively esterified OH group or another readily nucleophilically substitutable leaving group.

Claim 11 (Currently Amended) A process Process for the preparation of compounds of the formula I according to Claim 1, comprising reacting characterised in that a compound of the formula IV



in which R³ is as defined in Claim 1, and R⁴ is an amino-protecting group or H, is reacted, in a Michael-analogous reaction, with ethyl nitroacetate and diethylammonium chloride, and subsequently reducing the nitro group is subsequently reduced, to give a the compound of the formula V



and reacting the compound of the formula V is reacted with a compound conforming to the formula III.

Claim 12 (Canceled)

Claim 13 (Currently Amended) A pharmaceutical composition, Medicament comprising an effective amount of a compound of the formula I according to Claim 1, optionally in addition to one or more inert excipients, adjuvants and/or diluents, and a pharmaceutically acceptable carrier.

Claim 14 **(Currently Amended)** A composition Medicament according to Claim 13, further comprising characterised in that at least one additional further medicament active ingredient is present.

Claim 15 **(Currently Amended)** A process Process for the preparation of a composition medicament according to Claim 13, comprising combining characterised in that a compound of the formula I and, optionally if desired, a further medicament active ingredient is incorporated into one or more inert excipients and/or diluents by non-chemical methods.

Claim 16 **(Canceled)**

Claim 17 **(Currently Amended)** A method for treating Use of the compounds of the formula I according to Claim 16, characterised in that the diseases are selected from the group consisting of depression, strokes, cerebral ischaemia, extrapyramidal motor side effects of neuroleptics and of Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, brain or and spinal cord trauma, obsessive-compulsive disorder, sleeping disorders, tardive dyskinesia, learning disorders, age-related memory disorders, eating disorders, such as bulimia, and/or sexual dysfunctions, comprising administering to a host in need thereof a compound according to Claim 1.

Claim 18 **(Currently Amended)** A Medicament kit consisting of separate packs of

- a) an effective amount of a compound of the formula I according to Claim 1 and
an effective amount of a further medicament active ingredient.

Claim 19. **(New)** A method for treating depression, strokes, extrapyramidal motor side effects of neuroleptics and of Parkinson's disease, or Alzheimer's disease, comprising administering to a host in need thereof a compound according to Claim 1.